Longevity Health Outperforms Competitors in Volatility and Profitability

Longevity Health's share price is less volatile and more profitable than its industry peers

Published on Feb. 13, 2026

Got story updates? Submit your updates here. ›

A head-to-head comparison between Longevity Health (XAGE) and its competitors in the 'Surgical, Medical, And Dental Instruments And Supplies' industry shows that Longevity Health has a lower beta of 0.38, indicating its share price is 62% less volatile than the S&P 500. In contrast, Longevity Health's competitors have a higher average beta of 1.76, suggesting their share prices are 76% more volatile than the broader market. Additionally, Longevity Health outperforms its peers in key profitability metrics like net margins, return on equity, and return on assets.

Why it matters

This analysis highlights Longevity Health's relative stability and profitability compared to its industry competitors. Investors may find Longevity Health's lower volatility and stronger financials appealing, especially in the current economic climate. The data also suggests Longevity Health is well-positioned for long-term growth, with high institutional and insider ownership.

The details

Longevity Health has a beta of 0.38, meaning its share price is 62% less volatile than the S&P 500. In comparison, Longevity Health's competitors have an average beta of 1.76, indicating their share prices are 76% more volatile than the broader market. Additionally, Longevity Health outperforms its peers in key profitability metrics. 24.2% of Longevity Health's shares are held by institutional investors, compared to 22.5% for its industry. Insiders also hold a larger stake in Longevity Health at 29.0%, versus 18.1% for competitors. Despite lower revenue, Longevity Health has higher earnings and trades at a lower price-to-earnings ratio than its rivals.

The data and analysis were published on February 13, 2026.

The players